Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isoniazid Dose by NAT2 Polymorphism
NCT03665402Completed
- Sponsor
- Seoul National University Hospital
- Start
- May 2018
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of isoniazid in Tuberculosis (TB) (3 arms), sponsored by Seoul National University Hospital. Primary endpoint: Liver toxicity at 4 weeks. Started May 2018; status: completed.
02
Drugs
isoniazid
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT03665402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03665402.